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Introduction: The incidenceof pulmonaryhypertension (PH)
in pediatric patients after hematopoietic stem cell transplant
(SCT) is not known. PH is likely underdiagnosed in these
patients due to its non-speciﬁc presentation. We have
observed PH in critically ill SCT patients especially thosewith
transplant associated thromboticmicroangiopathy (TA-TMA).
Hence our goal was to determine the baseline incidence and
to establish the value of routine screening for PH after SCT
Hypothesis: PH occurs in pediatric patients after SCT and
echocardiographic screening may be of value in allowing
prompt diagnosis and intervention.
Methods: A multi-disciplinary practice guideline was
implemented in January 2012 requiring screening for PH in
SCT patients after transplant. All children had pre-transplant
echocardiography as well as echocardiography screening on
days +7, +30, and +100 after SCT, or at the time of ICU
admission if admitted to intensive care unit for known PH,
TA-TMA, respiratory or cardiovascular failure. Echocardiog-
raphy was repeated in 7 to 14 days if results were abnormal.
Patients were stratiﬁed as being “at risk” for, or having PH if
their right ventricular (RV) pressure was estimated at 35-49%
or >50% of systolic blood pressure, respectively.
Results: During an 8 month period, a total of 59 patients
were screened for PH (56 receiving allogeneic and 3
receiving autologous transplants), including 48 consecutive
SCT patients completing 100 days of scheduled screening
and 26 patients screened upon admission to the PICU. Fifteen
patients overlapped the two groups (screened both per
schedule on the ﬂoor and on admission to ICU). Fifteen
patients (25%) were determined to be “at risk” for PH, while 4
(7%) developed PH. Of the 48 patients screened during the
ﬁrst 100 days, 12 (25%) were determined to be “at risk”while
2 (4%) developed PH. Of the 26 patients admitted to the PICU,
7 (27%) were determined to be “at risk” while 4 (15%)
developed PH. Four patients admitted to the ICU received
speciﬁc therapy for PH with one requiring an atrial septos-
tomy for systemic RV pressure and associated low cardiac
output. The median time from transplant to abnormalechocardiography was 13 days. Elevated RV pressure was
signiﬁcantly associated with a diagnosis of TA-TMA (p¼ 0.03)
and presence of an oxygen requirement (p¼ 0.001).
Conclusions: PHmay occur following pediatric SCT. Targeted
echo screening of children, especially thosewith TA-TMA and
unexplained hypoxemia, may be beneﬁcial in detecting PH.
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NK cell transplantation has been increasingly used to
treat cancers that are resistant to chemotherapy. However,
not all cancers are susceptible to NK cell killing. The preva-
lence and mechanisms of NK cell resistance have not been
well elucidated. Because NKG2D is a major activating
receptor on NK cells, we sought to determine the speciﬁc role
of NKG2D pathway in tumor cell recognition. Herein, we
comprehensively assessed 20 cancer cell lines representing
a broad array of pediatric cancers. We found that only 30% of
them expressed high level of NKG2D ligands and were
susceptible to NK cell killing. The dependency on NKG2D
pathway in these NK susceptible cells was conﬁrmed by anti-
NKG2D antibody blocking experiments. For the 70% of cell
lines that were resistant to NK cells, 65% were due to
silencing of NKG2D ligand expression, whereas 35%were due
to insufﬁcient NKG2D activation. For the former cell lines,
NKG2D ligand expression was found to be downregulated at
the mRNA and/or protein level. By histone acetylation and/or
proteasome modulation, these regulatory checkpoints could
be circumvented to obtain sufﬁcient surface expression of
NKG2D ligands to overcomeNK resistance. For the cancer cell
lines that were NK resistant despite a high NKG2D ligand
expression, KIR inhibition was found to override NKG2D
activation in 80% of these cancers. MHC blockade success-
fully increased NK susceptibility of these cell lines. In the
remaining 20%, downregulation of ICAM-1 was responsible
for NK resistance. We conclude that NKG2D is the primary
pathway for tumor cell recognition in NK susceptible tumors.
Evasion of the NKG2D pathway is common through NKG2D-
ligand silencing, KIR inhibition, or inadequate expression of
adhesion molecules to mediate immune-synapse formation.
Because these resistance mechanisms are readily amenable
to therapeutic alteration, NK cell transplantation holds
promise for future cancer therapy.
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Background: Sickle cell anemia (SCA) is a chronic hemolytic
anemia with high morbidity and premature mortality.
Currently, the only available cure for SCA is allogeneic
